Skip to main content
Pharmaceutics logoLink to Pharmaceutics
. 2020 Dec 17;12(12):1220. doi: 10.3390/pharmaceutics12121220

Correction: López-Yerena, A., et al. “Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats” Pharmaceutics 2020, 12, 134

Anallely López-Yerena 1, Anna Vallverdú-Queralt 1,2, Raf Mols 3, Patrick Augustijns 3, Rosa M Lamuela-Raventós 1,2, Elvira Escribano-Ferrer 2,4,*
PMCID: PMC7766302  PMID: 33348931

The authors would like to make the following corrections to this paper [1]:

1. Change in Equation (1)

We have found two typographical errors in Equation (1) and we wish to replace

Peff=Øin2πRL×Ln CinCout.cor

With

Peff=Øin2πRL×Ln Cout.corCin

2. Change in Table 2

Table 2.

Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.

Test Compound Peff (×10−5 cm/s) Papp (×10−6 cm/s)
OLC 2.23 ± 3.16 4.12 * ± 2.33
LEV 7.64 ± 5.55 10.91 ± 6.27

* p < 0.05, Mann-Whitney U-test.

We have found a typographical error in the Peff heading in Table 2. In addition, and after reviewing the calculations again, we have detected that the data shown in Table 2 for levofloxacin did not consider the normalization of the 10-cm intestinal segment. With the normalization, the Peff value for levofloxacin increases (according to the length of the intestinal segment used). For these reasons, the authors wish to replace

With

Table 2.

Permeability coefficients (Peff) and apparent permeability coefficients (Papp) of oleocanthal and levofloxacin. Results are expressed as the mean ± SD of n = 4. Data are normalised to a 10-cm intestinal segment.

Test Compound Peff (×10−4 cm/s) Papp (×10−6 cm/s)
OLC 2.85 ± 2.63 4.12 * ± 2.33
LEV 12.69 ± 6.64 10.91 ± 6.27

* p < 0.05, Mann–Whitney U-test.

These changes do not affect the discussion and conclusions of the study. The authors would like to apologize for any inconvenience caused to the readers by these changes.

Conflicts of Interest

R.M.L.-R. reports receiving lecture fees from Cerveceros de España and receiving lecture fees and travel support from Adventia. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.López-Yerena A., Vallverdú-Queralt A., Mols R., Augustijns P., Lamuela-Raventós R.M., Escribano-Ferrer E. Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. Pharmaceutics. 2020;12:134. doi: 10.3390/pharmaceutics12020134. [DOI] [Google Scholar]

Articles from Pharmaceutics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES